The Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial marked a significant milestone in our approach to anticoagulation therapy in atrial fibrillation (AF). This groundbreaking study compared the efficacy and safety of dabigatran, a novel oral anticoagulant (NOAC), with the traditional warfarin. This article reviews the RE-LY trial and its transformative impact on the management […]